SCOHIA

Based in Japan, Scohia Pharma, Inc. , d. b. a SCOHIA, develops innovative therapeutics specializing in lifestyle-related diseases, focusing on enhancing treatment options for cardiovascular, metabolic, and renal health.

Scohia Pharma, Inc. is a specialty biotech company founded in 2017 and headquartered in Fujisawa, Japan. The firm is focused on developing treatments for lifestyle-related diseases and has completed two deals to date. In May 2026, Scohia Pharma, Inc.

raised JPY 3 billion in venture funding led by Beyond Next Ventures, with participation from Daiwa Corporate Investment, Kyoto Capital Partners and FRONTEO, Inc. , as well as DBJ Capital, SBI Investment, TOHOKU University Venture Partners and KSP also participated in the round. CEO Masanori Watanabe brings significant experience to the company, steering its growth and development in the competitive biotech landscape. Scohia Pharma, Inc.

specializes in developing innovative therapeutics aimed at lifestyle-related diseases, with a particular emphasis on cardiovascular, metabolic, and renal health. Their primary product, SCO-240, is a novel SSTR5 antagonist that demonstrates potential in addressing growth hormone-related disorders. The company undertakes clinical trials and product development across various regions, striving to address complex health issues faced by diverse patient populations globally. Their products are designed for use by healthcare providers and patients seeking advanced treatment alternatives for chronic conditions, ultimately aiming to improve patient outcomes in the markets they serve.

Scohia Pharma's revenue model comprises clinical trial funding, partnerships with healthcare providers, and anticipated sales from product offerings. The company engages in collaborations with pharmaceutical partners to facilitate clinical research and product commercialization. Revenue generation is expected to derive from licensing agreements and direct sales to healthcare providers once their products are approved and available in the market, establishing a sustainable business model through innovative healthcare solutions. In September 2024, Scohia Pharma, Inc.

secured JPY 560 million in venture funding, predominantly from DBJ Capital, intended to finance clinical trials for two new drugs targeting growth hormone deficiency and congenital adrenal hyperplasia. The company aims to expand its product pipeline with additional therapeutics designed to meet emerging health needs. Furthermore, Scohia Pharma plans to explore new geographic markets to enhance its global reach, although specific regions and timelines for these expansions have not been disclosed. The company will use the May 2026 funding to advance multiple clinical and preclinical drug development programs and expand its pipeline.